Sex differences in the onset and outcomes of immune checkpoint inhibitor-induced overt thyroid dysfunction: a retrospective study.
0/5 보강
APA
Bai Y, Yin Y, et al. (2025). Sex differences in the onset and outcomes of immune checkpoint inhibitor-induced overt thyroid dysfunction: a retrospective study.. Endocrine, 90(3), 1369-1379. https://doi.org/10.1007/s12020-025-04447-w
MLA
Bai Y, et al.. "Sex differences in the onset and outcomes of immune checkpoint inhibitor-induced overt thyroid dysfunction: a retrospective study.." Endocrine, vol. 90, no. 3, 2025, pp. 1369-1379.
PMID
41075126 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Gastrointestinal traits, common inflammatory disorders, gallstones, and biliary tract cancer: A network Mendelian randomization study.
- Exploration of a prognostic model for childhood acute lymphoblastic leukemia.
- Targeting microbiome-driven epigenetic modifications: a new frontier in breast cancer treatment.
- Stevioside inhibits colorectal cancer progression by regulating macrophage polarization.
- Prognostic significance and immune landscape of anoikis-related genes in hepatocellular carcinoma: a multi-omics analysis of subtypes and cellular communication.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- TIM-3 inhibition enhances breast tumor progression and metastasis: A paradoxical immune checkpoint response.
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.